Equillium Secures Clearance to Launch Phase 1 Trial of EQ504, with Dosing Expected by Early November
EQ sits 88% above its 52-week low of $0.756.
Summary
Equillium has received Australian regulatory clearance to begin its Phase 1 trial of EQ504, with dosing expected by early November 2026. The trial will evaluate safety, PK, and PD across three parts, including GI biopsies for target validation.
Key Events · Product Development and Regulatory · EQ
-
Phase 1 Trial Cleared
Australian HREC approval and TGA clearance have been received for the Phase 1 trial of EQ504, an oral AhR modulator.
-
Dosing Timeline Set
Dosing of healthy participants is expected to begin by early November 2026.
-
Trial Design Details
The three-part study includes a single ascending dose phase (5 cohorts), a multiple ascending dose phase (3 cohorts, 10-day dosing), and a food effect crossover; the dose range is 0.1-3.0 mg once daily.
-
Biomarker Validation
GI mucosal biopsies will measure CYP1A1 expression to confirm localized biological activity and provide target validation ahead of Phase 2.
Analysis · EQ · Life Sciences
Australian regulators have cleared Equillium to begin a Phase 1 trial of EQ504, an oral AhR modulator, with dosing of healthy participants expected by early November 2026. The study will include single and multiple ascending dose cohorts plus a food effect arm, and will use GI mucosal biopsies to measure CYP1A1 expression as a tissue-specific biomarker. For a company with a $92M market cap and cash runway into 2029, advancing its lead asset into the clinic provides a concrete near-term milestone and validates the drug's mechanism of action ahead of a planned Phase 2 proof-of-concept study.
How filings like this one have moved
In the 30 days to Oct 21, 2026, 28.9% of the 1511 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EQ was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $91.9M. The 52-week trading range was $0.76 to $3.54. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.